News

Biocon will hold a meeting of the Board of Directors of the Company on 7 May 2026.

Biocon announced that Health Canada has granted a Notice of Compliance (NOC) for Bosaya� (denosumab), a biosimilar to Prolia�, and Vezuo� (denosumab), a biosimilar to Xgeva�, on 03 April 2026. Both biosimilars were approved in the most common presentations: BOSAYA, as a 60 mg/mL injection for subcutaneous use in a prefilled syringe; and VEVZUO, as a 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial. Denosumab products play a key role in bone health by increasing bone mass and treating osteoporosis, as well as bone complications associated with cancer.Shreehas Tambe, CEO & Managing Director, Biocon, said, �Health Canada`s approval of BOSAYA and VEVZUO marks another important milestone for Biocon as we continue to expand access to high-quality biosimilars in key global markets. This approval reflects our strong scientific and regulatory capabilities and reinforces our commitment to patients living with osteoporosis and cancer-related bone conditions, while further strengthening our portfolio of affordable biologic therapies across immunology and oncology.�

The board of Biocon at its meeting held on 27 March 2026 has accepted the resignation of Mukesh Kamath, tendered vide his letter dated 20 March 2026, from the position of Interim Chief Financial Officer of the Company with effect from close of business hours of 31 March 2026 to take up another role within the Biocon Group.Further, the board has approved the appointment of Kedar Narayan Upadhye, Chief Financial Officer of Biocon Biologics, as the Chief Financial Officer (Key Managerial Personnel and Senior Management Personnel) of the Company, with effect from 01 April 2026. Powered by Capital Market - Live News

The board of Biocon at its meeting held on 27 March 2026 has approved the appointment of Shreehas Pradeep Tambe (DIN: 09796480), Chief Executive Officer and Managing Director of Biocon Biologics (BBL), as an Additional Director of the Company w.e.f. 01 April 2026 and Chief Executive Officer and Managing Director (Key Managerial Personnel of the Company) for a period of 5 (five) years effective from 01 April 2026, subject to the approval of the shareholders of the Company. Powered by Capital Market - Live News

The board of Biocon at its meeting held on 27 March 2026 has accepted the resignation of Siddharth Mittal (DIN: 03230757), tendered vide his letter dated 20 March 2026, from the position of Chief Executive Officer and Managing Director of the Company w.e.f. close of business hours of 31 March 2026 to transit into another leadership role within the Biocon Group. Powered by Capital Market - Live News